Birth weight of infants born to pregnant women living with human immunodeficiency virus and its associated factors
10.3760/cma.j.cn311365-20221008-00416
- VernacularTitle:人类免疫缺陷病毒阳性孕妇所生婴儿的出生体质量及其影响因素
- Author:
Jinli LIU
1
;
Songjie WU
;
Shi ZOU
;
Ling FENG
;
Yajun YAN
;
Yuting TAN
;
Fangzhao MING
;
Mingqi LUO
;
Ke LIANG
Author Information
1. 武汉大学中南医院感染科，武汉 430071
- Keywords:
HIV;
Birth weight;
Prevention of mother-to-child transmission;
Protease inhibitors
- From:
Chinese Journal of Infectious Diseases
2023;41(6):401-406
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the birth weight (BW) of infants born to pregnant women living with human immunodeficiency virus (HIV) and its associated factors, and to provide more evidence for the prevention of mother-to-child transmission (PMTCT) in China.Methods:This study was a retrospective cohort study. Between January 2004 and December 2021, pregnant women living with HIV and their infants in Hubei Province were recruited and followed up, and clinical data were collected through hospital medical records and HIV/acquired immunodeficiency syndrome comprehensive response information management system. The multivariable linear regression was performed on the collected data to investigate associated influencing factors of BW.Results:In total, 531 pregnant women living with HIV (581 pregnancies) and 581 infants were enrolled. Of the 581 infants, 36 were HIV-positive, with a PMTCT rate of 6.2%. The mean BW of the infants was (3 075.0±470.2) gram. Protease inhibitor (PI) based-anti-retroviral therapy (ART) ( β=-0.1, 95% confidence interval ( CI)-188.2 to -37.1, P=0.004), ART in the first trimester( β=-0.1, 95% CI -201.9 to -65.5, P<0.001), infant HIV infection ( β=-0.1, 95% CI -310.4 to -68.2, P=0.002), hepatitis C virus infection ( β=0.1, 95% CI 71.2 to 410.4, P=0.005) and gestational age ( β=0.6, 95% CI 155.9 to 191.5, P<0.001) were associated with decreased BW. Conclusions:While improving the effectiveness of PMTCT for HIV, more attention should be paid to pregnant women who received ART in the first trimester and PI-based ART for preventing lower BW and improving maternal and infantile health.
